share_log

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Intelligent Bio Solutions | 8-K:智能生物解決方案公佈2025財年第一季度未經審計的初步收入業績
美股SEC公告 ·  10/30 04:19

Moomoo AI 已提取核心訊息

On October 29, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced preliminary unaudited revenue results for its fiscal first quarter ending September 30, 2024. The company reported an increase in revenue of approximately $0.87 million, marking a 10% rise year-on-year and a 20% increase quarter-on-quarter. Intelligent Bio Solutions highlighted the growing importance of its cartridge sales, which are expected to become the primary revenue driver due to their higher profit margins and recurring nature. The company's Intelligent Fingerprinting Drug Screening System, which utilizes these cartridges, is gaining traction with over 400 active customer accounts, signaling confidence in the product and contributing to a steady stream of recurring revenue. Additionally, the company has expanded its distribution network in Saudi Arabia, aiming to meet the increasing global demand for drug testing solutions. The full financial results for the quarter will be disclosed in the upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in the week commencing November 4, 2024.
On October 29, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced preliminary unaudited revenue results for its fiscal first quarter ending September 30, 2024. The company reported an increase in revenue of approximately $0.87 million, marking a 10% rise year-on-year and a 20% increase quarter-on-quarter. Intelligent Bio Solutions highlighted the growing importance of its cartridge sales, which are expected to become the primary revenue driver due to their higher profit margins and recurring nature. The company's Intelligent Fingerprinting Drug Screening System, which utilizes these cartridges, is gaining traction with over 400 active customer accounts, signaling confidence in the product and contributing to a steady stream of recurring revenue. Additionally, the company has expanded its distribution network in Saudi Arabia, aiming to meet the increasing global demand for drug testing solutions. The full financial results for the quarter will be disclosed in the upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in the week commencing November 4, 2024.
2024年10月29日,總部位於特拉華州的醫療科技公司Intelligent Bio Solutions Inc.宣佈了截至2024年9月30日的財政第一季度的初步未經審計營業收入結果。公司報告了約87萬美元的營業收入增長,同比增長10%,環比增長20%。 Intelligent Bio Solutions強調了其墨盒銷售的日益重要性,預計由於其更高的利潤率和可重複利潤特性,這些墨盒銷售將成爲主要的收入驅動力。公司的Intelligent Fingerprinting Drug Screening System利用這些墨盒,正得到超過400個活躍客戶帳戶的認可,表明了對產品的信懇智能,並有助於穩定的可重複收入。此外,公司已在沙特阿拉伯擴大了其分銷網絡,旨在滿足全球對藥物檢測解決方案不斷增長的需求。該季度的完整財務結果將在即將提交給美國證券交易委員會(SEC)的《10-Q表》季度報告中披露,提交日期爲2024年11月4日當週。
2024年10月29日,總部位於特拉華州的醫療科技公司Intelligent Bio Solutions Inc.宣佈了截至2024年9月30日的財政第一季度的初步未經審計營業收入結果。公司報告了約87萬美元的營業收入增長,同比增長10%,環比增長20%。 Intelligent Bio Solutions強調了其墨盒銷售的日益重要性,預計由於其更高的利潤率和可重複利潤特性,這些墨盒銷售將成爲主要的收入驅動力。公司的Intelligent Fingerprinting Drug Screening System利用這些墨盒,正得到超過400個活躍客戶帳戶的認可,表明了對產品的信懇智能,並有助於穩定的可重複收入。此外,公司已在沙特阿拉伯擴大了其分銷網絡,旨在滿足全球對藥物檢測解決方案不斷增長的需求。該季度的完整財務結果將在即將提交給美國證券交易委員會(SEC)的《10-Q表》季度報告中披露,提交日期爲2024年11月4日當週。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息